NDAINTRAVENOUSSOLUTION
Approved
Oct 2022
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE (norepinephrine bitartrate) by Infinant Health is (alpha-adrenergic action) and an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action). First approved in 2022.
Drug data last refreshed 43m ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Norepinephrine bitartrate in 0.9% sodium chloride is an IV catecholamine vasopressor approved in 2022 for acute hypotensive states in critical care settings. It functions as both an alpha-adrenergic vasoconstrictor and beta-adrenergic cardiac inotrope with coronary vasodilation properties. The formulation leverages patent-protected delivery technology extending exclusivity through 2038.
Peak11.2 years to LOE
Product is at peak commercial phase with no direct generic competition; small ICU-focused sales team with stable to growing revenue trajectory.
Mechanism of Action
(alpha-adrenergic action) and an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action).
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on norepinephrine bitartrate offers mid-career stability in a specialized critical care niche with limited competitive disruption through 2038. Career trajectory emphasizes clinical credibility, hospital relationship management, and formulary positioning rather than rapid portfolio expansion.
Hospital/ICU Account ManagerMedical Science Liaison (Critical Care)
Worked on NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE at Infinant Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.